ALKERMES | ALKS - Market Capitalization


ALKERMES reported $7.46B in Market Capitalization this September of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 444.6B 59.91B Jun/2026
Acadia Pharmaceuticals USD 4.33B 537M Jun/2026
ALKERMES USD 8.73B 2.85B Jun/2026
Amgen USD 195.44B 5.55B Jun/2026
Biogen USD 31.9B 5B Jun/2026
BioMarin Pharmaceutical USD 11.06B 196M Jun/2026
Bristol-Myers Squibb USD 117.66B 6.17B Jun/2026
Coherus Biosciences USD 172M 19M Dec/2025
Eli Lilly USD 1.13T 260.54B Jun/2026
Gilead Sciences USD 156.86B 16.13B Jun/2026
Heron Therapeutics USD 238M 7M Dec/2025
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
J&J USD 611.36B 32.21B Jun/2026
Malin Corporation EUR 133.52M 29.05M Aug/2026
Merck USD 317.37B 20.27B Jun/2026
Nektar Therapeutics USD 2.12B 1.26B Mar/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Otsuka Holdings JPY 5.87T 111.31B Jun/2026
Ovoca Bio EUR 1.17M 18.38K Dec/2025
Pfizer USD 138.44B 15.37B Jun/2026
Regeneron Pharmaceuticals USD 65.37B 16.31B Jun/2026
Vertex Pharmaceuticals USD 126.07B 12.49B Jun/2026